Ribociclib

Ribociclib is a member of piperazines and a member of pyridines. Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali. Ribociclib is a Kinase Inhibitor. The mechanism of action of ribociclib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor. It is grouped under the following drug class(es): Antineoplastic agents, CDK4/6 Inhibitors, Kinase inhibitors and QTc-prolonging agents. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Kisqali, 7-Cyclopentyl-N, N-dimethyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)-7H-pyrrolo[2, 3-d]pyrimidine-6-carboxamide and LEE-011. Its PubChem CID is 44631912.

CAS No 1211441-98-3
Molecular Formula C23H30N8O
Molecular Weight 434.5 g/mol
Synonyms 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide

Frequently Asked Questions